- Home
- NFBK vs DNA Comparison
NFBK vs DNA Comparison
Compare NFBK & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- DNA
- Stock Information
- Founded
- NFBK 1887
- DNA 2008
- Country
- NFBK United States
- DNA United States
- Employees
- NFBK N/A
- DNA N/A
- Industry
- NFBK Major Banks
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NFBK Finance
- DNA Health Care
- Exchange
- NFBK Nasdaq
- DNA Nasdaq
- Market Cap
- NFBK 406.5M
- DNA 466.4M
- IPO Year
- NFBK 2007
- DNA N/A
- Fundamental
- Price
- NFBK $11.88
- DNA $11.42
- Analyst Decision
- NFBK Buy
- DNA Sell
- Analyst Count
- NFBK 2
- DNA 3
- Target Price
- NFBK $13.00
- DNA $9.67
- AVG Volume (30 Days)
- NFBK 208.6K
- DNA 1.4M
- Earning Date
- NFBK 07-23-2025
- DNA 08-07-2025
- Dividend Yield
- NFBK 4.43%
- DNA N/A
- EPS Growth
- NFBK 1.58
- DNA N/A
- EPS
- NFBK 0.76
- DNA N/A
- Revenue
- NFBK $128,407,000.00
- DNA $237,417,000.00
- Revenue This Year
- NFBK $12.68
- DNA N/A
- Revenue Next Year
- NFBK $15.15
- DNA $15.81
- P/E Ratio
- NFBK $15.42
- DNA N/A
- Revenue Growth
- NFBK N/A
- DNA 13.76
- 52 Week Low
- NFBK $8.92
- DNA $5.00
- 52 Week High
- NFBK $14.39
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- NFBK 54.85
- DNA 64.12
- Support Level
- NFBK $11.19
- DNA $8.21
- Resistance Level
- NFBK $11.87
- DNA $10.02
- Average True Range (ATR)
- NFBK 0.34
- DNA 0.69
- MACD
- NFBK -0.05
- DNA 0.09
- Stochastic Oscillator
- NFBK 63.81
- DNA 84.19
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.